	US 11,833,134 B1
	Polymeric clotrimazole biofilm for the treatment of otomycosis
Mai Mostafa Khalaf Ali, Al-Ahsa (SA); Hany Mohamed Abd El-Lateef Ahmed, Al-Ahsa (SA); Ahmed Mohammed Abu-Dief Mohammed, Al-Madina Al-Mounawara (SA); Amr Embaby Elsayed Karamany, Assuit (EG); Mahmoud Ibrahim Mahmoud Abdelmagid, Assuit (EG); Mohammed Sherif Saddik Ibrahim, Sohag (EG); and Ali Khames Abd Eltwab Morsy, Sohag (EG)
Assigned to KING FAISAL UNIVERSITY, Al-Ahsa (SA)
Filed by KING FAISAL UNIVERSITY, Al-Ahsa (SA)
Filed on Feb. 6, 2023, as Appl. No. 18/165,085.
Int. Cl. A61K 31/4174 (2006.01); A61P 27/16 (2006.01); A61P 31/10 (2006.01); A61K 9/46 (2006.01); A61K 47/10 (2017.01); A61K 47/38 (2006.01); A61K 9/70 (2006.01); A61K 9/00 (2006.01)

CPC A61K 31/4174 (2013.01) [A61K 9/0046 (2013.01); A61K 9/7007 (2013.01); A61K 47/10 (2013.01); A61K 47/38 (2013.01); A61P 27/16 (2018.01); A61P 31/10 (2018.01)]

4 Claims

1. A polymeric biofilm for the treatment of otomycosis, comprising:

a biocompatible polymer matrix comprising hydroxypropylmethylcellulose (HPMC);

a pharmaceutically active ingredient for the treatment of fungal infections mixed with and uniformly dispersed in the polymer matrix, wherein said active ingredient is clotrimazole or a pharmaceutically acceptable salt thereof; and

a plasticizer added to the mixture of the biocompatible polymer matrix and the pharmaceutically active ingredient, the plasticizer formulating the mixture as a biofilm adapted for application through an external canal of an ear of a patient infected by otomycosis over a tympanic membrane of the ear for treatment thereof;

wherein said pharmaceutically active ingredient and said biocompatible polymer are present in the mixture in a ratio of 1:3 pharmaceutically active ingredient: biocompatible polymer matrix; and

wherein said active ingredient and said biocompatible polymer are present in the mixture in a ratio of 10 mg clotrimazole/1.0 cm²polymer matrix.